You are here

Share:

Search Technologies

Showing 1-20 of 55 results found

A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays

Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ataxia telangiectasia-mutated and Rad3-related (ATR) kinase phosphorylated at threonine 1989. The antibody can be used for pharmacodynamic assays to quantify drug action on the ATR target.

Diagnostic Assays for the Detection of Thyroid Cancer

The Eunice Kennedy Shriver National Institute of Child and Human Development’s (NICHD) Pediatric Growth and Nutrition Branch seek partners to co-develop a diagnostic assay to detect thyroid cancer.

Urine-based Diagnostic Assay for the Early Detection of Cancer

Researchers at the NCI have developed a urine-based diagnostic platform capable of predicting the onset of cancer. This high-throughput screening method quantifies metabolites to assess cancer risk, determine disease prognosis and monitor response to therapy.

Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy

Somatic mutations can alter the sensitivity of tumors to T-cell mediated immunotherapy. Identifying genes that positively regulate the sensitivity of cancer cells to T-cell mediated clearance is key for effective treatment in cancer patients. Researchers at the National Cancer Institute (NCI) have identified a panel of genes which are useful in predicting a patient’s response to immunotherapy. NCI seeks partners to co-develop or license the technology toward commercialization.

Gene Signature for Predicting Solid Tumors Patient Prognosis

The National Cancer Institute’s Laboratory of Human Carcinogenesis seeks parties to license or co-develop a method of predicting the prognosis of a patient diagnosed with hepatocellular carcinoma (HCC) or breast cancer by detecting expression of one or more cancer-associated genes, and a method of identifying an agent for use in treating HCC.

Ratio Based Biomarkers for the Prediction of Cancer Survival

The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.

High-throughput Assay to Identify New Cancer Drugs

The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

Biomarker signature development: microRNAs for biodosimetry

Alterations in microRNAs (miRNAs), a type of small non-coding RNAs, have been reported in cells/tumors subjected to radiation exposure, implying that miRNAs play an important role in cellular stress response to radiation. NCI researchers evaluated small non-coding RNAs, long non-coding RNAs (lncRNA), and mRNA, as potential non-invasive biomarkers for radiation biodosimetry. The NCI Radiation Oncology Branch seeks parties interested in licensing or co-development of RNA biomarker signature(s) for radiation biodosimetry.

Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome

There are currently no methodologies that allow for epigenome, genome and transcriptome analysis all in a single cell. In addition, there are currently no methodologies that permit repeating the results of these analyses on the same single cells. Scientists at the National Cancer Institute (NCI) Laboratory of Cellular Oncology have developed a method for generating a “reusable” single cell that allows for repeated experiments on the same cell. Utilizing this methodology epigenomic, genomic, and transcriptomic analysis can be performed on the same cell. NCI seeks parties to license or co-develop the technology through research collaborations.

Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy

Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.

Pages